KOSDAQBiotech & Pharma199730

BioInfra

₩1,440▲ 15.66%2026-11-18 close
Market Cap
₩7B
Turnover
₩1.3B
Volume
860K
Shares out.
4.9M
PER
—
PBR
0.5×
EPS
-₩1,106
Dividend Yield
20.98%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩300 per share · Prices as of the 2026-11-18 close

01

Report overview

Quarterly Profit Turn, Annual Losses Remain the Test

BioInfra swung to a quarterly operating profit in Q2 2026 but returned to an operating loss in Q3, and its 2025 net loss attributable to controlling shareholders widened to KRW 9.13 billion, so the move to sustained profitability is still in progress.

  1. 1

    Operating profit of KRW 75.71 million in Q2 2026 marked a quarterly turn to profit, but Q3 2026 returned to an operating loss of KRW 145 million.

  2. 2

    Q3 2026 revenue reached KRW 10.9 billion, up 116.1% year on year, and revenue has risen for two consecutive quarters since the Q1 2026 low.

  3. 3

    On an annual basis, the company posted operating losses of KRW 5.12 billion in 2024 and KRW 6.28 billion in 2025, and a 2025 net loss attributable to controlling shareholders of KRW 9.13 billion.

  4. 4

    The debt-to-equity ratio rose to 112.0% at the end of 2025 from 49.2% in 2024, and operating cash flow turned negative at KRW -1.5 billion.

  5. 5

    Media reported in October 2026 that an absorption merger with a related company is under way.

02

Business structure

BioInfra is a contract research organization (CRO) that conducts clinical trials for pharmaceutical clients, with its core businesses in bioequivalence (BE) studies, Phase 1 clinical trials and bioanalysis of samples.

It listed on KOSDAQ in March 2023 and is classified under natural sciences and engineering R&D services. Based on pre-listing materials, its 2021 revenue mix was 72.3% BE studies, 18.2% Phase 1 clinical trials and 7.8% clinical and non-clinical sample analysis.

BE studies are required for generic drug approval, so generic drug developers are the main clients. Media reported that the company ranked first in MFDS BE study approvals in 2021 with a 23.6% share. It expanded into pharmaceutical quality control (QC) and was designated a testing institution by MFDS in June 2025.

However, as of the first half of 2025, pharmaceutical testing accounted for only 0.55% of total revenue and regulatory clinical trials for 0.36%, so the revenue base remains concentrated in BE studies.

The company attributed the Q2 2026 revenue growth to wider BE and clinical trial orders and higher sample analysis volumes. In competition, BioInfra is classified as a specialist CRO in BE studies, sharing the market with Phase 1-focused providers and larger full-service contractors. Media reported in October 2026 that an absorption merger with a related company, Yoo&Infra, is under way.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩5.1B-₩2.1B−40.5%
2025Q4₩6.6B-₩900M−13.7%
2026Q1₩5.5B-₩2.4B−43.8%
2026Q2₩8.5B₩75,712,6980.9%
2026Q3₩10.9B-₩100M−1.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩35.4B₩6.4B₩6.2B18.0%34.8%82.0%
2023₩30.1B₩1.3B₩2B4.3%5.9%38.4%
2024₩23.8B-₩5.1B-₩4B−21.5%−14.4%49.2%
2025₩23.1B-₩6.3B-₩9.1B−27.1%−55.4%112.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On the DART-filed figures, revenue fell from KRW 35.4 billion in 2022 to KRW 30.1 billion in 2023 (down 15.0% year on year), KRW 23.8 billion in 2024 (down 20.9%) and KRW 23.1 billion in 2025 (down 2.9%), a decline in each of the three years from 2023 to 2025, with 2022 the largest year and 2025 the smallest in the 2022 to 2025 window.

Operating profit dropped from KRW 6.36 billion in 2022 to KRW 1.31 billion in 2023 (down 79.5%), turned into an operating loss of KRW 5.12 billion in 2024, and the loss widened to KRW 6.28 billion in 2025.

Net profit attributable to controlling shareholders fell from KRW 6.24 billion in 2022 to KRW 2 billion in 2023 (down 67.9%), then became a net loss of KRW 3.98 billion in 2024 and KRW 9.13 billion in 2025, two consecutive loss years.

Net income including non-controlling interests matched these amounts in 2022 and 2025. The operating margin declined from 18.0% in 2022 to 4.3% in 2023, -21.5% in 2024 and -27.1% in 2025.

A September 2025 report said the company attributed the cost increase to fixed costs from headcount growth around its listing and new business initiatives, and that employee benefit expenses rose from KRW 6 billion in 2022 to KRW 8.9 billion in 2024 while R&D expenses rose from KRW 4 billion to KRW 7 billion over the same period.

Quarterly, the operating loss narrowed from KRW 2.05 billion in Q3 2025 to KRW 902 million in Q4 2025, then widened to KRW 2.41 billion in Q1 2026.

Q2 2026 revenue of KRW 8.5 billion came with a return to operating profit of KRW 75.71 million, while Q3 2026 revenue of KRW 10.9 billion came with an operating loss of KRW 145 million.

Q3 2026 net profit attributable to controlling shareholders of KRW 699 million turned positive year on year, so operating and net results moved in different directions, and the non-operating items behind that gap are a point to check in the annual report.

Over the last four quarters, the net loss attributable to controlling shareholders totaled KRW 5.38 billion. Operating cash flow went from KRW 8.42 billion in 2022 to KRW 679 million in 2023 and KRW 1.73 billion in 2024, then turned to a KRW -1.5 billion outflow in 2025.

05

Industry analysis

In the CRO market where BioInfra operates, BE studies are required for generic drug approval, so demand moves with the number of generic development projects.

A 2023 report pointed to a rise in BE study volumes from the second half of that year into the following year, tied to deadlines for submitting BE results, but that outlook dates from 2023 and should be checked against current order flows.

The 23.6% share in MFDS BE approvals refers to 2021 and may not reflect today's ranking. A 2024 report noted that funding conditions for biotech clients drive clinical outsourcing demand.

A 2024 report estimated Korea's pharmaceutical quality control market at over KRW 50 billion, which the company has targeted with its new business. Positioning-wise, BioInfra has been described as a specialist in BE studies and as a Phase 1-focused CRO.

Because scale and fixed cost structures differ widely from large biopharma operators, margins are hard to compare directly. The DART-filed results also show that its profitability has swung more sharply than many larger peers.

06

Outlook

After its July 2026 earnings disclosure, the company said it would keep expanding orders and diversifying its portfolio in the second half, building on its core CRO capabilities. It attributed Q2 2026 revenue growth to wider BE and clinical trial orders and higher sample analysis volumes.

The quality testing business, designated by MFDS in June 2025, still contributes a small share of revenue, so how much it adds is a point to watch. The Q3 2026 operating loss of KRW 145 million meant the Q2 profit did not carry forward, so second-half profitability depends on order volume and cost control.

In September 2025 the company said its profitability would improve once new business revenue ramped up, while the same report noted that new business revenue had not yet reached full scale.

Media reported in October 2026 that an absorption merger with a related company is under way, and the effect of the merger on earnings and capital structure is also a point to check. An early October 2026 report flagged that exchange guidance related to market capitalization requirements has yet to be resolved.

No annual forecast has been disclosed as a DART-filed figure, so the earnings direction will be read from quarterly disclosures until the 2026 annual report.

07

Valuation

PER
—
PBR
0.5×
ROE
-32.2%
EPS
-₩1,106
BPS
₩2,741
Dividend per share
₩300

Because the company has posted net losses attributable to controlling shareholders over the last four quarters, its price-to-earnings ratio cannot be calculated. The price-to-book ratio places the stock in a range where the share price sits well below book value per share, a discount to net assets.

Total equity at the end of 2025 was KRW 16.5 billion, equal to the equity attributable to controlling shareholders, with no non-controlling interests. Because accumulated losses have been reducing equity, the discount to net assets should be read alongside the pace at which losses narrow.

The dividend yield is well above the sector average, but the earnings that fund dividends were negative, so the sustainability of payouts depends on whether profitability holds. Past PER levels were formed during profitable periods, so they are hard to compare directly with ratios based on post-loss results.

Media in October 2026 noted that the share price moved sharply up and down over a short period. Valuation context therefore comes down to two facts: whether quarterly profits continue, and how fast equity shrinks or rebuilds.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Quarterly profit turn and revenue growth

Operating profit of KRW 75.71 million in Q2 2026 marked a quarterly turn to profit, and net profit attributable to controlling shareholders of KRW 1.51 million also turned positive. Revenue rose for two consecutive quarters after the Q1 2026 low, reaching KRW 8.5 billion in Q2 and KRW 10.9 billion in Q3.

Q3 2026 net profit attributable to controlling shareholders of KRW 699 million turned positive year on year. Compared with KRW 5.07 billion in Q3 2025, the revenue base is larger.

Wider BE and clinical orders plus sample analysis

The company cited wider BE and clinical trial orders and higher sample analysis volumes as drivers of Q2 2026 revenue growth. After the July 2026 disclosure, a company representative said order expansion and portfolio diversification would continue in the second half. BE demand is tied to generic approvals, so sustained order flow could broaden the revenue base.

A new base in quality testing

Designation as a quality testing institution by MFDS in June 2025 established a base for pharmaceutical testing. Testing accounted for only 0.55% of revenue in the first half of 2025, so the business is still at an early stage.

A 2024 report estimated Korea's pharmaceutical quality control market at over KRW 50 billion, which frames the opportunity.

09

Bear factors

Annual losses and a brief profit stretch

The company recorded operating losses of KRW 5.12 billion in 2024 and KRW 6.28 billion in 2025, two straight loss years, and the 2025 net loss attributable to controlling shareholders widened to KRW 9.13 billion. The four-quarter net loss attributable to controlling shareholders totaled KRW 5.38 billion.

The profit in Q2 2026 was a single quarter and Q3 2026 returned to an operating loss, so sustainability is a task for the quarters ahead.

Rising leverage and weaker cash flow

The debt-to-equity ratio rose to 112.0% at the end of 2025 from 49.2% in 2024, with total liabilities of KRW 18.5 billion. Operating cash flow turned to a KRW -1.5 billion outflow in 2025. A September 2025 report pointed out that total borrowings exceeded cash and cash equivalents.

Order volatility and exchange guidance

A 2024 report noted that BE orders weakened at times when biotech clients lacked funding. The exchange guidance is tied to market capitalization requirements, so changes in market capitalization bear on whether it is resolved. The same month, reports described sharp single-day share price moves, so short-term volatility is a burden.

10

Risk factors

Order volatility

Most revenue comes from BE studies, so quarterly sales move with generic approvals and client timing. Revenue hit a low in Q1 2026 and rose in Q2 and Q3, but continued growth is not assured. Because the quality testing business is still small, it offers limited cushion against gaps in orders.

Liquidity and leverage

Total equity at the end of 2025 was KRW 16.5 billion against total liabilities of KRW 18.5 billion, with a debt-to-equity ratio of 112.0%. Operating cash flow of KRW -1.5 billion in 2025 means continued losses could raise repayment pressure. A September 2025 report noted that borrowings exceeded cash and cash equivalents.

Listing requirements and merger

An early October 2026 report flagged exchange guidance related to market capitalization. An absorption merger with a related company is in progress, and its terms could change how results and the capital structure are read. The timetable has only been reported and should be confirmed through the official filing.

11

What to watch next

  1. By March 31, 2027 (annual report filing deadline)

    The 2026 annual report will confirm Q4 2026 results, full-year operating and net results attributable to controlling shareholders, operating cash flow and the debt-to-equity ratio. Whether these match the quarterly figures is the check point.

  2. By May 15, 2027 (Q1 2027 quarterly report deadline)

    Whether operating profit returns after the Q3 2026 operating loss is the key check, showing whether the Q2 2026 profit was a one-quarter event.

  3. At the merger effective date (date not confirmed)

    Once the effective date and terms of the absorption merger with a related company are disclosed, the effect on earnings and capital structure should be checked.

  4. When the exchange guidance is resolved (deadline not confirmed)

    Whether the exchange guidance tied to market capitalization is resolved, and the company's disclosures during that process, should be checked.

12

Overall view

BioInfra swung to a quarterly operating profit of KRW 75.71 million in Q2 2026, and Q3 2026 revenue of KRW 10.9 billion rose 116.1% year on year. However, Q3 2026 returned to an operating loss of KRW 145 million, and the four-quarter net loss attributable to controlling shareholders totaled KRW 5.38 billion.

On an annual basis the company posted operating losses in both 2024 and 2025, with a debt-to-equity ratio of 112.0% and operating cash flow of KRW -1.5 billion at the end of 2025. Revenue is concentrated in BE studies and sensitive to order flow, while the quality testing business is still small.

On the market side, exchange guidance and an absorption merger with a related company are under way. Bullish factors are the revenue recovery and the first quarterly profit in several periods, while bearish factors are the continued annual losses and financial burden.

The next checkpoints are the annual profit and loss in the 2026 annual report and the direction of operating profit in Q1 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. comp.fnguide.com
  2. comp.wisereport.co.kr
  3. ssl.pstatic.net
  4. ibtomato.com
  5. eugenefn.com
  6. markets.hankyung.com
  7. medipharmhealth.co.kr
  8. pharm.edaily.co.kr
  9. digitaltoday.co.kr
  10. pharm.edaily.co.kr
  11. job-post.co.kr
  12. hankyung.com
  13. job-post.co.kr
  14. job-post.co.kr
  15. m.news.nate.com

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis